Arvinas, Inc. (ARVN) Stock Price & Analysis
Arvinas, Inc. (ARVN) rose 0.84% to USD 7.21 as of June 10, 2026 at 02:26 UTC, according to Nexqual real-time market data.
ARVN last closed at USD 7.15; the session ranged USD 7.01–7.37 on volume of 981,343 shares. Market capitalization is $465.20M, with a 52-week range of USD 6.06–14.51 (NMS). Source: Nexqual, June 10, 2026 at 02:26 UTC.
Key Statistics (as of June 10, 2026 at 02:26 UTC)
| Price | USD 7.21 |
|---|---|
| Change | ▲ 0.84% (up) |
| Previous Close | USD 7.15 |
| Open | USD 7.22 |
| Day Range | USD 7.01 – 7.37 |
| 52-Week Range | USD 6.06 – 14.51 |
| Volume | 981,343 shares |
| Market Cap | $465.20M |
| Exchange | NMS |
Technical Analysis (ARVN)
Nexqual's technical model rates ARVN "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:26 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.36 (oversold) |
| vs SMA50 | Below (USD 9.81) |
| MACD | -0.73 (negative) |
Analyst Ratings (ARVN)
Wall Street analysts rate ARVN "Buy" based on 16 analysts, with a mean price target of USD 15 (range USD 6–24), per Nexqual as of June 10, 2026 at 02:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 15 |
| High Target | USD 24 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 9 / 8 / 1 |
Earnings (ARVN)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.33 |
| Revenue Estimate | $57.43M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.9 vs est -0.96 ▲ beat |
| 2025-12-31 | USD -1.1 vs est -0.57 ▼ miss |
| 2025-09-30 | USD -0.48 vs est -0.74 ▲ beat |
| 2025-06-30 | USD -0.84 vs est -0.89 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:26 UTC.
Financials & Fundamentals (ARVN)
| Total Revenue | $89.40M |
|---|---|
| Revenue Growth (YoY) | -91.70% |
| Gross Margin | +134.45% |
| Operating Margin | -405.13% |
| Profit Margin | -247.54% |
| ROE | -42.28% |
| Debt / Equity | 2.17 |
| Current Ratio | 5.44 |
| Total Cash | $614.90M |
| Total Debt | $8.40M |
| Free Cash Flow | $-199.64M |
Source: Nexqual, June 10, 2026 at 02:26 UTC.
Financial Health Score (ARVN)
Nexqual rates Arvinas, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:26 UTC.
| Growth | Weak — Revenue -0% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $615M cash vs $8M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$200M, burning cash |
| Efficiency | Critical — ROE -42%, ROA -18.9% |
Ownership (ARVN)
| Insider Ownership | +7.76% |
|---|---|
| Institutional Ownership | +83.28% |
| Shares Outstanding | 64.52M |
| Float | 55.95M |
| Short % of Float | +8.52% |
Source: Nexqual, June 10, 2026 at 02:26 UTC.
Leadership (ARVN)
Arvinas, Inc. is led by Randy Teel (age 45), CEO, President & Director, per Nexqual as of June 10, 2026 at 02:26 UTC.
| CEO, President & Director | Randy Teel (age 45) |
|---|---|
| CFO & Treasurer | Andrew R. Saik (age 56) |
| Chief Scientific Officer | Angela M. Cacace (age 57) |
| Vice President of Investor Relations | Jeff Boyle |
| Senior Vice President of Regulatory Affairs | Paul McInulty |
Major Backers & Investors (ARVN)
Notable institutional backers of Arvinas, Inc. include Shaw D.E. & Co., Inc., Pfizer Inc, TCG Crossover Management, LLC, according to Nexqual as of June 10, 2026 at 02:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Shaw D.E. & Co., Inc. | 5.64% |
| Pfizer Inc | 5.36% |
| TCG Crossover Management, LLC | 3.7% |
| Armistice Capital, LLC | 3.07% |
| Two Sigma Investments, LP | 2.84% |
| Fidelity | 1% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.13% |
| BlackRock | 13.86% |
| State Street | 2.83% |
| Geode Capital | 2.41% |
Source: Nexqual, June 10, 2026 at 02:26 UTC.
From Arvinas, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- We have designed and optimized our proprietary PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression.
- We have also created a proprietary software tool to accelerate LEAP library design. • PROTACify : We have built PROTACify, a proprietary computational, machine-learning, or ML, solution for modeling PROTAC ternary complexes to enable selection of the best PROTAC designs for synthesis.
- We believe favorable clinical trial results in our ongoing oncology and neurology programs would further validate our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins.
- With our integrated capabilities we aim to accelerate discovery of TPD therapeutics, translating biological insight into efficient drug design.
Partnerships
- In July 2021, we announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
| DNLI | Denali Therapeutics Inc. | USD 20.79 | ▲ 6.51% |
| RCKT | Rocket Pharmaceuticals, Inc. | USD 2.65 | ▼ 3.64% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
| RCUS | Arcus Biosciences, Inc. | USD 23.64 | ▲ 1.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:26 UTC. This page is informational and not investment advice.